Treatment patterns of romosozumab in postmenopausal women with severe osteoporosis in Denmark: findings from the ROmosozumab in Scandinavia real-world Evidence Study (ROSES)

This study provides real-world insight into patient and prescriber characteristics, and patterns and factors of romosozumab use across Denmark. Whilst a notable proportion of patients received romosozumab first in sequential therapy, there is still opportunity to optimize bone mineral density (BMD) outcomes with osteoanabolic agents used first, followed by an antiresorptive, in patients at high fracture risk. Of romosozumab-treated patients with 15 months follow-up data, most were assumed to continue romosozumab for 11-15 months when treatment transition was recorded. Real-world data from Danish registries were used to describe treatment patterns with romosozumab and other anti-osteoporosis treatments in postmenopausal women with osteoporosis. The study found romosozumab‑treated patients were younger and had fewer comorbidities than other osteoporosis patients. Among romosozumab-treated patients, 44.5% were treatment-naïve and most continued with romosozumab for 11-15 months.